Spiroxins, DNA cleaving antitumor antibiotics from a marine-derived fungus

Tetrahedron Letters

Volumn 40, Issue 13, 1999, Pages 2489-2492

  McDonald, Leonard A ^a   Abbanat, Darren R ^a   Barbieri, Laurel R ^a   Bernan, Valerie S ^a   Discafani, Carolyn M ^a   Greenstein, Michael ^a   Janota, Katarzyna ^a   Korshalla, Joseph D ^a   Lassota, Piotr ^a   Tischler, Mark ^a   Carter, Guy T ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; SPIROXIN A; SPIROXIN B; SPIROXIN C; SPIROXIN D; SPIROXIN E; UNCLASSIFIED DRUG;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DNA CLEAVAGE; DRUG CYTOTOXICITY; DRUG ISOLATION; DRUG STRUCTURE; FUNGUS; NUCLEAR OVERHAUSER EFFECT; STEREOCHEMISTRY; STRUCTURE ANALYSIS;

EID: 0033605871     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4039(99)00242-7     Document Type: Article

References (16)

1. Barrett, A. G. M.; Hamprecht, D.; Meyer, T. Chem. Commun 1998, 809-810.
2. Schlingmann, G.; Matile, S.; Berova, N.; Nakanishi, K.; Carter, G. T. Tetrahedron 1996, 52, 435-46.
3. King, I.; Blood, C.; Chu, M.; Patel, M.; Liu, M.; Li, Z.; Robertson, N.; Maxwell, E.; Catino, J. J. Oncol. Res. 1995, 7, 1-5.
4. Weber, H. A.; Baenziger, N. C.; Gloer, J. B. J. Am. Chem. Soc. 1990, 112, 6718-19.
5. Weber, H. A.; Gloer, J. B. J. Org. Chem. 1991, 56, 4355-60.
6. Singh, S. B.; Zink, D. L.; Liesch, J. M.; Ball, R. G.; Goetz, M. A.; Bolessa, E. A.; Giacobbe, R. A.; Silverman, K. C.; Bills, G. F.; Lingham, R. B. J. Org. Chem. 1994, 59, 6296-302.
7. Shimada, A.; Hosoya, T. Antibacterial Decalone Spiroketal Derivative F-12517, its manufacture with Vibrissea, and pharmaceuticals containing it: Jpn. Kokai Tokkyo Koho, 1998.
8. This is due to the lack of teleomorph morphology. The culture would be included as a member of the class Deuteromycetes or Fungi Imperfecti.
9. Difco potato dextrose broth, pH 7.0.
10. 6, ppm downfield from TMS) 193.9 (1′), 190.5 (1), 154.2 (9′), 152.7 (9), 140.9 (6′), 137.6 (5), 133.8 (6), 127.9 (7), 125.7 (7′), 124.3 (8), 123.2 (5′), 118.8 (8′), 111.4 (10), 109.3 (10′), 103.5 (4), 83.7 (4′), 53.5 (2), 53.3 (2′), 51.5 (3), 51.4 (3′).
11. 6, ppm downfield from TMS) 198.2 (1′), 193.8 (1), 153.0 (9′), 157.1 (9), 144.0 (6′), 137.0 (5), 140.7 (6), 131.0 (7), 128.0 (7′), 127.9 (8), 125.8 (5′), 125.0 (8′), 114.8(10), 113.7 (10′), 103.20 (4), 86.5 (4′), 56.1 (2), 56.2 (2′), 54.2 (3), 54.0 (3′).
12. 3, ppm downfield from TMS) 191.3 (1′), 194.2 (1), 119.8 (9′), 159.7 (9), 149.3 (6′), 139.2 (5), 134.1 (6), 127.1 (7), 122.5 (7′), 119.5 (8), 124.9 (5′), 130.5 (8′), 109.1 (10), 125.7 (10′), 103.6 (4), 84.7 (4′), 53.2 (2), 53.5 (2′), 52.4 (3), 51.7 (3′).
13. 4, ppm downfield from TMS) 193.4 (1′), 158.3 (9), 151.3 (6′), 136.0 (5), 135.8 (6), 131.0 (8′), 127.8 (10′), 127.0 (5′), 123.2 (7′), 120.2 (7), 119.8 (9′), 119.0 (8), 116.8 (10), 107.1 (4), 85.1 (4′), 67.5 (1), 56.4 (2), 54.6 (3′), 53.3 (2′), 51.5 (3).
14. 6, ppm downfield from TMS) 66.0 (1′), 190.7 (1), 146.4 (9′), 152.5 (9), 141.1 (6′), 137.6 (5), 134.2 (6), 127.0 (7), 124.2 (8), 120.4 (8′), 118.9 (5′), 117.2 (10′), 116.5 (7′), 111.5 (10), 103.1 (4), 84.8 (4′), 54.0 (2′), 53.4 (2), 51.5 (3), 49.9 (3′).
15. Boyd, M. R.; Paull, K. D. Drug Dev. Res. 1995, 34, 91-109.
16. O'Brien, P. J. Chem.-Biol. Interact. 1991, 80, 1-41.